OncoMatch/Clinical Trials/NCT06675357

Using FAPI PET/MRI to Evaluate Prostate Cancer

Is NCT06675357 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for prostate cancer metastatic disease.

Phase 2RecruitingUniversity of Wisconsin, MadisonNCT06675357Data as of May 2026

The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Disease stage

Metastatic disease required

Prostate Cancer Metastatic Disease

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of Wisconsin · Madison, Wisconsin

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify